Form 3 - Initial statement of beneficial ownership of securities

                                POWER OF ATTORNEY

      The undersigned, as a Section 16 reporting person of PMV Pharmaceuticals,
Inc. (the "Company"), hereby constitutes and appoints David H. Mack, Ph.D.,
and Robert Ticktin, and each of them, as the undersigned's true and
lawful attorney-in-fact to:

      1. complete and execute Forms 3, 4 and 5 and other forms and all
amendments thereto as such attorney-in-fact shall in his discretion
determine to be required or advisable pursuant to Section 16 of the Securities
Exchange Act of 1934 (as amended) and the rules and regulations promulgated
thereunder, or any successor laws and regulations, as a consequence of the
undersigned's ownership, acquisition or disposition of securities of the
Company; and

      2. do all acts necessary in order to file such forms with the SEC,
any securities exchange or national association, the Company and such other
person or agency as the attorneys-in-fact shall deem appropriate.

      The undersigned hereby ratifies and confirms all that said attorneys-in-
fact and agents shall do or cause to be done by virtue hereof.  The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the undersigned, are not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with Section 16
of the Securities Exchange Act of 1934 (as amended).

      This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the foregoing attorneys-in-fact.

      IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of December 31, 2023.

      				Signature: /s/  Michael Carulli
      				Print Name:	Michael Carulli

PMV Pharmaceuticals (NASDAQ:PMVP)
Historical Stock Chart
From Oct 2024 to Nov 2024